Onvatilimab, also known as JNJ-61610588, represents a promising therapeutic antibody targeting {PD-1 | the PD-1 receptor ) and currently undergoing evaluation for multiple {cancer | malignant diseases ) indications . This engineered IgG4 monoclonal antibody exhibits significant promise in preventing PD-1 interaction with its counterparts , thus rel